Literature DB >> 19587378

Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance.

Simona Blotta1, Pierfrancesco Tassone, Rao H Prabhala, Piersandro Tagliaferri, David Cervi, Samir Amin, Jana Jakubikova, Yu-Tzu Tai, Klaus Podar, Constantine S Mitsiades, Alessandro Zullo, Brunella Franco, Kenneth C Anderson, Nikhil C Munshi.   

Abstract

The transformation from monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) is thought to be associated with changes in immune processes. We have therefore used serologic analysis of recombinant cDNA expression library to screen the sera of MGUS patients to identify tumor-associated antigens. A total of 10 antigens were identified, with specific antibody responses in MGUS. Responses appeared to be directed against intracellular proteins involved in cellular functions, such as apoptosis (SON, IFT57/HIPPI), DNA and RNA binding (ZNF292, GPATCH4), signal transduction regulators (AKAP11), transcriptional corepressor (IRF2BP2), developmental proteins (OFD1), and proteins of the ubiquitin-proteasome pathway (PSMC1). Importantly, the gene responsible for the oral-facial-digital type I syndrome (OFD1) had response in 6 of 29 (20.6%) MGUS patients but 0 of 11 newly diagnosed MM patients. Interestingly, 3 of 11 (27.2%) MM patients after autologous stem cell transplantations showed responses to OFD1. We have confirmed T-cell responses against OFD1 in MGUS and observed down-regulation of GLI1/PTCH1 and p-beta-catenin after OFD1 knock-down with specific siRNA, suggesting its functional role in the regulation of Hh and Wnt pathways. These findings demonstrate OFD1 as an important immune target and highlight its possible role in signal transduction and tumorigenesis in MGUS and MM.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19587378      PMCID: PMC2759650          DOI: 10.1182/blood-2009-04-219436

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  51 in total

1.  The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.

Authors:  Nicholas Mitsiades; Constantine S Mitsiades; Paul G Richardson; Vassiliki Poulaki; Yu-Tzu Tai; Dharminder Chauhan; Galinos Fanourakis; Xuesong Gu; Charles Bailey; Marie Joseph; Towia A Libermann; Robert Schlossman; Nikhil C Munshi; Teru Hideshima; Kenneth C Anderson
Journal:  Blood       Date:  2002-11-07       Impact factor: 22.113

Review 2.  Tumour-associated antigens in multiple myeloma.

Authors:  Catherine Pellat-Deceunynck
Journal:  Br J Haematol       Date:  2003-01       Impact factor: 6.998

3.  AKAP-4: a novel cancer testis antigen for multiple myeloma.

Authors:  Maurizio Chiriva-Internati; Raffaele Ferrari; Yuefei Yu; Cody Hamrick; Nicoletta Gagliano; Fabio Grizzi; Eldo Frezza; Marjorie R Jenkins; Fred Hardwick; Nicholas D'Cunha; W Martin Kast; Everardo Cobos
Journal:  Br J Haematol       Date:  2008-02       Impact factor: 6.998

4.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew F Plevak; L Joseph Melton
Journal:  N Engl J Med       Date:  2002-02-21       Impact factor: 91.245

5.  Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome.

Authors:  H M Lokhorst; A Schattenberg; J J Cornelissen; M H van Oers; W Fibbe; I Russell; N W Donk; L F Verdonck
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

6.  Serologic analysis of ovarian tumor antigens reveals a bias toward antigens encoded on 17q.

Authors:  Brad Stone; Michèl Schummer; Pamela J Paley; Lucas Thompson; Julie Stewart; Molly Ford; Meghan Crawford; Nicole Urban; Kathy O'Briant; Brad H Nelson
Journal:  Int J Cancer       Date:  2003-03-10       Impact factor: 7.396

7.  Genomic abnormalities in monoclonal gammopathy of undetermined significance.

Authors:  Rafael Fonseca; Richard J Bailey; Gregory J Ahmann; S Vincent Rajkumar; James D Hoyer; John A Lust; Robert A Kyle; Morie A Gertz; Philip R Greipp; Gordon W Dewald
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

8.  Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression.

Authors:  M J Scanlan; I Gout; C M Gordon; B Williamson; E Stockert; A O Gure; D Jäger; Y T Chen; A Mackay; M J O'Hare; L J Old
Journal:  Cancer Immun       Date:  2001-03-30

9.  Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.

Authors:  S Vincent Rajkumar; Ruben A Mesa; Rafael Fonseca; Georgene Schroeder; Matthew F Plevak; Angela Dispenzieri; Martha Q Lacy; John A Lust; Thomas E Witzig; Morie A Gertz; Robert A Kyle; Stephen J Russell; Philip R Greipp
Journal:  Clin Cancer Res       Date:  2002-07       Impact factor: 12.531

10.  A phase 2 study of bortezomib in relapsed, refractory myeloma.

Authors:  Paul G Richardson; Bart Barlogie; James Berenson; Seema Singhal; Sundar Jagannath; David Irwin; S Vincent Rajkumar; Gordan Srkalovic; Melissa Alsina; Raymond Alexanian; David Siegel; Robert Z Orlowski; David Kuter; Steven A Limentani; Stephanie Lee; Teru Hideshima; Dixie-Lee Esseltine; Michael Kauffman; Julian Adams; David P Schenkein; Kenneth C Anderson
Journal:  N Engl J Med       Date:  2003-06-26       Impact factor: 91.245

View more
  22 in total

Review 1.  Vaccines targeting cancer stem cells: are they within reach?

Authors:  Madhav V Dhodapkar; Kavita M Dhodapkar
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

2.  Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.

Authors:  Jacalyn Rosenblatt; Baldev Vasir; Lynne Uhl; Simona Blotta; Claire Macnamara; Poorvi Somaiya; Zekui Wu; Robin Joyce; James D Levine; Dilani Dombagoda; Yan Emily Yuan; Karen Francoeur; Donna Fitzgerald; Paul Richardson; Edie Weller; Kenneth Anderson; Donald Kufe; Nikhil Munshi; David Avigan
Journal:  Blood       Date:  2010-10-28       Impact factor: 22.113

Review 3.  Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma.

Authors:  Brendan M Weiss; W Michael Kuehl
Journal:  Expert Rev Hematol       Date:  2010-04       Impact factor: 2.929

4.  Identification of a novel fusion gene, IRF2BP2-RARA, in acute promyelocytic leukemia.

Authors:  C Cameron Yin; Nitin Jain; Meenakshi Mehrotra; Jianhua Zhagn; Alexei Protopopov; Zhuang Zuo; Naveen Pemmaraju; Courtney DiNardo; Cheryl Hirsch-Ginsberg; Sa A Wang; L Jeffrey Medeiros; Lynda Chin; Keyur P Patel; Farhad Ravandi; Andrew Futreal; Carlos E Bueso-Ramos
Journal:  J Natl Compr Canc Netw       Date:  2015-01       Impact factor: 11.908

Review 5.  Latest advances and current challenges in the treatment of multiple myeloma.

Authors:  Anuj Mahindra; Jacob Laubach; Noopur Raje; Nikhil Munshi; Paul G Richardson; Kenneth Anderson
Journal:  Nat Rev Clin Oncol       Date:  2012-02-21       Impact factor: 66.675

Review 6.  Immunity to stemness genes in human cancer.

Authors:  Madhav V Dhodapkar
Journal:  Curr Opin Immunol       Date:  2010-02-09       Impact factor: 7.486

7.  Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma.

Authors:  Simona Blotta; Jana Jakubikova; Teresa Calimeri; Aldo M Roccaro; Nicola Amodio; Abdel Kareem Azab; Umberto Foresta; Constantine S Mitsiades; Marco Rossi; Katia Todoerti; Stefano Molica; Fortunato Morabito; Antonino Neri; Piersandro Tagliaferri; Pierfrancesco Tassone; Kenneth C Anderson; Nikhil C Munshi
Journal:  Blood       Date:  2012-07-20       Impact factor: 22.113

8.  Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma.

Authors:  Larry D Anderson; Danielle R Cook; Tori N Yamamoto; Carolina Berger; David G Maloney; Stanley R Riddell
Journal:  Cancer Immunol Immunother       Date:  2011-04-03       Impact factor: 6.968

Review 9.  Spontaneous and therapy-induced immunity to pluripotency genes in humans: clinical implications, opportunities and challenges.

Authors:  Madhav V Dhodapkar; Kavita M Dhodapkar
Journal:  Cancer Immunol Immunother       Date:  2010-11-23       Impact factor: 6.968

Review 10.  Cancer immunoprevention.

Authors:  Olivera J Finn; Pamela L Beatty
Journal:  Curr Opin Immunol       Date:  2016-01-19       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.